Reuters Health Information (2014-03-18): France's Ipsen says Dysport incontinence treatment trial positive

Drug & Device Development

France's Ipsen says Dysport incontinence treatment trial positive

Last Updated: 2014-03-18 14:02:44 -0400 (Reuters Health)

PARIS (Reuters) - French drugmaker Ipsen said it had seen positive results from the first stage of a phase II trial of its Dysport brand in treating patients with a certain type of urinary incontinence.

Ipsen said that there had been a mean reduction of more than 75% in urinary incontinence episodes for trial patients suffering from neurogenic detrusor overactivity, a chronic condition involving abnormal bladder contractions linked to an underlying neurological condition such as multiple sclerosis.

"These results were achieved with a single dose of Dysport 750 units injected in either 15 or 30 sites in the detrusor muscle. Efficacy was confirmed by improvement in urodynamic parameters and quality of life. The safety profile observed in the study is consistent with the safety profile expected in this indication," the company said.

"These results are very encouraging for the Dysport franchise, which has the opportunity of potentially expanding into urology," Ipsen said.

Dysport is an injectable form of botulinum toxin type A (BTX-A), which is isolated and purified from Clostridium BTX-A bacteria.